Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047379 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Neonc Technologies.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 6
- Study locations
NCT06047379 is a Phase 1 study of Colorectal Cancer and Gastric Cancer that is actively recruiting participants, run by Neonc Technologies. The registered enrollment target is 134 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT06047379, a Phase 1 study of Colorectal Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Neonc Technologies.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 6
- Study locations
Study Summary
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Regorafenib
- DRUG NEO212 Oral Capsule
Study Locations (6)
California
- Precision NextGen Oncology - Beverly Hills
- OPN Healthcare, Inc - Glendale
- University of Southern California - Los Angeles
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor, Scott and White Research Institute - Dallas
Washington
- Northwest Medical Specialties - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06047379
The ClinicalTrials.gov registry entry for NCT06047379 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Neonc Technologies, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06047379 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT06047379 about?
NCT06047379 is a clinical study titled "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis". This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the ...
What is the current status of trial NCT06047379?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2023-11-01. Estimated completion is 2027-08-31.
What conditions does trial NCT06047379 study?
This clinical trial studies the following conditions: Colorectal Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06047379?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Regorafenib (DRUG), NEO212 Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT06047379?
This trial is sponsored by Neonc Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06047379 being conducted?
This trial has 6 study locations across California, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.